SOUTH SAN FRANCISCO, Calif.,
Oct. 29, 2019 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it
will report its third quarter 2019 financial results after market
close on Tuesday, November 5,
2019. Rigel senior management will follow the announcement
with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial
results.
Participants can access the live conference call by dialing
(877) 407-3088 (domestic) or (201) 389-0927 (international).
The conference call and accompanying slides will also be webcast
live and can be accessed from Rigel's website at
www.rigel.com. The webcast will be archived and
available for replay for 90 days after the call via the Rigel
website.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc., is a biotechnology company
dedicated to discovering, developing and providing novel small
molecule drugs that significantly improve the lives of patients
with immune and hematologic disorders, cancer and rare diseases.
Rigel's pioneering research focuses on signaling pathways that are
critical to disease mechanisms. The company's first FDA approved
product is TAVALISSE® (fostamatinib disodium hexahydrate), the only
oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of
adult patients with chronic immune thrombocytopenia who have had an
insufficient response to a previous treatment. Rigel's current
clinical programs include a Phase 3 study of fostamatinib in
autoimmune hemolytic anemia (AIHA); a recently completed Phase 1
study of R835, a proprietary molecule from its interleukin receptor
associated kinase (IRAK) program; and an ongoing Phase 1 study of
R552, a proprietary molecule from its receptor-interacting protein
kinase (RIP1) inhibitor program. In addition, Rigel has product
candidates in clinical development with partners Aclaris
Therapeutics, AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.
Please see www.TAVALISSE.com for the full Prescribing
Information.
Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2019-financial-results-300946892.html
SOURCE Rigel Pharmaceuticals, Inc.